Bile acid biosynthesis 7a-Hydroxy-4-cholesten-3-one 7a,12a-Dihydroxy-4-cholesten-3-one Hydroxy-D 5 steroid dehydrogenase, Cholesterol oxidase X-ray analysis a b s t r a c t This paper describes a method for the chemical synthesis of 7a,12a-dihydroxy-4-cholesten-3-one (1a) and its biological precursor, 7a-hydroxy-4-cholesten-3-one (1b), both of which are key intermediates in the major pathway of bile acid biosynthesis from cholesterol. The principal reactions involved were (1) building of the cholesterol (iso-octane) side chain by 3-carbon elongation of the cholane (iso-pentane) one, (2) oxidation sequence to transform the 3a-hydroxy group of the steroidal A/B-ring to the desired 4-en-3-one system, and (3) appropriate protection strategy for hydroxy groups in the positions at C-7 and C-12 in the steroid nucleus. The absolute structure of 1a and 1b were confirmed by NMR and X-ray crystallography. The targeted compounds 1a and 1b, prepared in 11 steps from 2a and 2b respectively, should be useful for biochemical studies of bile acid biosynthesis or clinical studies of bile acid metabolism, as plasma levels of 1b (also termed C4) have been shown to correlate highly with the rate of bile acid biosynthesis in man.
Introduction
Bile acids are synthesized by the liver from cholesterol by a complex series of reactions involving at least 14 enzymatic steps [1a,1b] . In humans, a failure of any of these enzymatic reactions will result in accumulation of intermediates in the bile acid biosynthesis pathway, as well as a deficiency in the normal primary bile acids, cholic acid (CA; 2a) and chenodeoxycholic acid (CDCA; 2b). Defective bile acid biosynthesis presents clinically as liver disease in infants and may be fatal unless treated by bile acid replacement therapy; such therapy is life-saving [2, 3] .
As shown in Fig. 1 , the initial biosynthetic transformation of cholesterol to the primary bile acids (2a and 2b) involves sequential 7a-hydroxylation (catalyzed by cholesterol 7a-hydroxylase, Cyp7A1) followed by C-3 oxidation and concomitant double bond migration (catalyzed by a C 27 3b-hydroxy-D 5 -C 27 -steroid oxidoreductase, HSD3B7) to form 7a-hydroxy-4-cholesten-3-one (1b), which is a precursor of CDCA (2b) [1c] . The transformation of 1a catalyzed by the microsomal steroid 12a-hydroxylase Cyp8b1 leads to the formation of 7a,12a-dihydroxy-4-cholesten-3-one (1a), which is ultimately converted to CA (2a) [1d] .
The two unsaturated oxysterols (1a and 1b) are thus pivotal biosynthetic intermediates in the so-called ''neutral'' pathway of primary bile acid biosynthesis and are of sustained interest in the biosynthetic, biological, physiological, and metabolic studies of bile acids [3] . In addition, the plasma level of 1b has been shown to correlate highly with the rate of bile acid biosynthesis [4] , and is thus a useful non-invasive biomarker for detecting increased bile acid biosynthesis. Such a determination is useful in patients with idiopathic diarrhea to determine whether bile acid malabsorption is present, as the compensatory increase in bile acid synthesis may lead to chronic diarrhea, because of bile acid induced secretion in the large intestine [5] .
For the accurate analysis of 1a and 1b in plasma, authentic reference compounds are needed. Although 1b is available from 0039 Abbreviations: CYP7A1, cholesterol 7a-hydroxylase; HSD3B7, 3b-hydroxy-D 5 -C 27 -steroid oxidoreductase; TEMPO, 2,2,6,6-tetramethylpiperidine 1-oxyl free radical; IBX, 2-iodoxybenzoic acid. commercial sources, it is extremely expensive. 1a is not marketed. To our knowledge, however, the chemical synthesis of 1a and 1b, which have a D 4 -3-oxo-7a-hydroxy structure in the steroid nucleus and the iso-octane (cholestane) side chain at the C-17 position, has not yet been reported. During the course of our studies on bile acid metabolism in vertebrates, we required 1a and 1b as authentic reference standards. We report here the chemical synthesis of 1a and 1b using inexpensive reagents and readily available steroid sources. Very recently, Björkhem have reviewed his five decades with oxysterols, particularly for 1b [Biochimie 2013;95:448-54].
Results and discussion

Enzymatic synthesis
Alexander and Fisher reported some years ago a convenient enzymatic synthesis of 7a-hydroxy-4-cholesten-3-one (1b) by the hydroxypropyl-b-cyclodextrin-facilitated cholesterol oxidase oxidation of 5-cholestene-3b,7a-diol (7a-hydroxycholesterol) [6] . In this enzymatic synthesis using cholesterol oxidase (from Brevibacterium sp.) and catalase, there is a simultaneous oxidation of the 3b-hydroxy group to the 3-oxo group and migration of the double bond from D 5 to D 4 ; this procedure has been used for the preparation of D
4
-3-oxo-7a-hydroxy steroids [7] . In preliminary work, we developed an improved enzymatic method for the preparation of 1b and its 7b-isomer, by the route shown in Fig. 2 . However, such an enzymatic synthesis is expensive, does not yield a pure product, and is useful only on a micromolar scale. Furthermore, a major shortcoming of this enzymatic synthesis is its inability to generate 7a,12a-dihydroxy-4-cholesten-3-one (1a), the metabolic precursor of cholic acid, a major primary bile acid in vertebrates.
Thus, we described herein an alternative, non-enzymatic chemical preparation of 1a and 1b, starting from easily available commercial materials.
Chemical synthesis
We report here synthesis of 1a, the target compound, from 2a in 11 steps, according to the route shown in Fig. 3 . The principal steps consisted of (1) the elongation (by three carbon atoms) of the C 5 cholane (iso-pentane) side-chain in 2a to the C 8 cholestane (iso-octane) side chain in five steps and (2) the transformation of the A/B-ring structure into the 3-oxo-D 4 -7a,12a-dihydroxy steroid nucleus in six steps. Our initial effort was directed to the construction of the cholestane side-chain from 2a. Reduction of the terminal carboxyl group to the corresponding primary alcohol is usually carried out with LiAlH 4 under strong alkaline conditions. However, this reduction technique has a disadvantage, as it also causes partial or complete hydrolysis of the acetyl protecting groups at C-3, C-7 and C-12 in 3a. Therefore, we explored the use of less basic NaBH 4 , combined with ethyl chloroformate and triethylamine (Et 3 N) [8] . Thus, CA peracetate, 3a, prepared from 2a by the usual method, was treated with NaBH 4 /ethyl chloroformate/Et 3 N in dry THF to give the corresponding 24-hydroxy-3a,7a,12a-triacetate 4a. As expected, the reduction reaction proceeded smoothly via the anhydride derivative of 3a as an intermediate without hydrolysis of the acetyl groups. Preliminary experiments revealed that the conversion of 4a to the corresponding 3a,7a,12a-triacetoxy-24-aldehyde (5a) by the use of pyridinium chlorochromate (PCC) and pyridinium dichromate (PDC) as oxidants was unsatisfactory; the yield was less than 60% and required tedious purification of the desired product by chromatography. However, when 4a was subjected to oxidation with sodium hypochlorite (NaClOÁnH 2 O) in the presence of catalytic amounts of 2,2,6,6-tetramethylpiperidine1-oxyl (as free radical; TEMPO) in a NaHCO 3 buffer solution [9] , mild, selective oxidation of the C-24 primary alcohol 4a took place, to afford the corresponding C-24 aldehyde 5a in good isolated yield of 79%.
Subsequent Wittig reaction of 5a with isopropylphenylphosphonium iodide in the presence of n-BuLi at 0°C for 15 min, yielded the unsaturated D 24 -3,7,12-triacetate 6a having the C 8 branched side chain. Although the basic conditions resulted concurrently in partial or complete deprotection of the acetyl groups at C-7 and C-12 in 6a, these mixtures were re-acetylated without difficulty. Catalytic hydrogenation of 6a using 10% Palladium on carbon (Pd/C) catalyst in a solvent mixture of EtOAc-methanolacetic acid under slightly positive pressure proceeded smoothly to afford 5b-cholestan-3a,7a,12a-triacetate (7a) exclusively. Thus, the elongation of the C 5 side chain by three carbon atoms to form the C 8 cholestane side chain was accomplished in 5 steps from 2a; the total yield of 7a from 2a was ca. 40%. The C 27 triacetate 7a, when treated with methanolic HCl at 30°C, was deprotected regioselectively at the equatorially-oriented 3a-acetyl group to yield 7a,12a-diacetoxy-5b-cholestan3a-ol (8a), Subsequent oxidation of 8a with Jones reagent, followed by complete alkaline hydrolysis (using 10% methanolic KOH) of the resulting 3-oxo-7a,12a-diacetoxy derivative (9a) proceeded cleanly to give 7a,12a-dihydroxy-5b-cholestan-3-one (10a) nearly quantitatively.
The choice of a suitable protecting group for the 7a-and 12a-hydroxy groups in 10a was an essential factor for subsequent reactions. In our exploratory works, attempted dehydrogenation of 9a with IBX (see below) was successful, but subsequent hydrolysis of the resulting 7a,12a-diacetoxy-4-cholesten-3-one failed. Under the various alkaline hydrolysis conditions that were examined, allylic elimination of the 7a-acetyl group took place to give a mixture of 12a-hydroxy-4,6-cholestadien-3-one and 12a-acetoxy-4,6-cholestadien-3-one as the major products. To prevent the elimination, we protected the 7a-and 12a-hydroxy groups as formate derivatives. The diformyloxy-5b-cholestan-3-one (11a) was found to be preferable to 9a as a substrate for the IBX reaction, because the formate is more labile and the deprotection is much easy under mild conditions. The compound 11a was prepared nearly quantitatively from 10a by the usual formic acid/ HClO 4 method [10] .
Our preliminary experiments revealed that dehydrogenation of 11a with iodoxybenzene catalyzed by benzeneselenic anhydride was successful [10] , but that selective hydrogenation of the D 1 -bond of the resulting 7a,12a-diformyloxy-1,4-choladien-3-one was unsuccessful. An attempt at direct oxidation of 11a with selenium dioxide [11] to give 7a,12a-diformyloxy-4-cholesten-3-one (12a) also failed.
Recently the report of a new, powerful dehydrogenation oxidant, o-iodoxybenzoic acid (IBX), prompted us to apply this reagent for the preparation of the targeted 12a from 11a. Nicolaou et al. [12] have reported that IBX, a readily available hypervalent iodine (V) reagent, oxidizes ketones efficiently to the conjugated enones or dienones, and benzylamines to the amines. In addition, IBX was found to be highly effective in mediating dehydrogenations adjacent to carbonyl functionalities (to form a,b-unsaturated carbonyl compounds) as well as at benzylic and related carbon centers (to form conjugated aromatic carbonyl systems). In the IBX-mediated dehydration, some 3-oxo-5a-steroids (trans A/B-ring juncture) have been shown to be converted to the corresponding 3-oxo-D 1 enones or 3-oxo-D 1,4 dienones, depending on the experimental conditions. However, Li and Tochtrop [13] have recently reported that IBX smoothly and regioselectively performs the dehydrogenation of 3-oxo-5b-steroids (cis A/B-ring juncture) to give the 3-oxo-D 4 enones, probably owing to the stereochemical difference of the A/B-rings in the steroid nucleus. When 11a was treated with freshly prepared IBX (see Section 3) [14] in DMSO containing trifluoroacetic acid at 40°C for 40 h, the dehydrogenation reaction took place as expected at the hydrogen atoms attached to C-4 and C-5 to give the desired a,b-unsaturated ketone, 7a,12a-diformyloxy-4-cholesten-3-one (12a), in moderate yield (50%), without being accompanied by the elimination of the 7a-formyl group. Also, the undesirable products -3-oxo-D -7,12-diformate -as well as the other by-products, were not formed at all. Based on a suggestion of Nicolaou et al. [12] , a possible ionic-mechanism for the dehydrogenation of 11a by IBX suggests that the reaction is initiated by single electron transfer from the substrate 11a to IBX to form a radical cation which reacts further to give the desired 12a.
We found that the use of commercially available stabilized IBX (SIBX), which contains 55 wt.% of 2-iodobenzoic acid as a stabilizer, was unsatisfactory, because it lacked reproducibility, and often resulted in a complicated mixture of products. Isolation of 12a was tedious and time-consuming, and as a result, was obtained in low yield.
In the final step, the usual alkaline hydrolysis of 12a with aqueous NaOH at room temperature for 30 min gave the targeted 7a,12a-dihydroxy-4-cholesten-3-one (1a). In this hydrolysis reaction of 12a, the elimination product -3-oxo-4,6-diene -was produced (2%). On the other hands, when 12b was treated with aqueous NaOH, 3-oxo-4,6-diene was detected 2% as by-product (yields were established by HPLC). Thus, our successful strategy for obtaining the desired changes in the steroid nucleus was based on solving two problems -first was selection of the appropriate protecting groups for the hydroxy groups of 2a and 2b and the second was the use of a modified IBX as the dehydrogenation reagent. Analogous 7a-hydroxy-4-cholesten-3-one (1b) (lacking a 12a-hydroxy group) was also prepared starting from CDCA (2b) by essentially the same procedures as described in detail for the preparation of 1a from 2a. Overall yields of 1a and 1b in 11 steps were ca. 6.5% and 7.4%, respectively.
NMR properties
In the 1 H-NMR spectrum of 1a, a pair of doublets appearing at 0.86 and 0.87 ppm were assigned to the three protons at C-26 and C-27 in the terminal isopropyl methyl groups, providing evidence for the structure of the C 8 cholestane side-chain. The 19-H 3 signal (singlet) in 1a was appreciably shifted downfield by 0.19 ppm and resonated at 1.19 ppm, compared to that in 10a (1.00 ppm), whereas a signal appearing at 5.82 ppm as a singlet was assigned to the 4-H. These observations indicated that 1a has the 3-oxo-D 4 -7a-hydroxy structure in the A/B-ring juncture [15] . Furthermore, the occurrence of the two quaternary 13 C signals at 198.7 and 167.4 ppm and the tertiary 13 C signal at 126.9 ppm in the 13 C-NMR spectrum of 1a also indicated the presence of the conjugated enone moiety. The 2D HMBC spectrum of 1a showed the correlation peaks between 19-H 3 vs C-5 and 4-H vs C-5, strongly indicating the presence of the D
4
-bond. Essentially identical 1 H-and 13 C-NMR characteristics were observed in the spectra of 1b.
X-ray analysis of 1b
The molecular structure of 7a-hydroxy-4-cholesten-3-one (1b) was determined by X-ray analysis. Data for crystallographic details, atomic coordinates, and selected bond lengths (Å) and angles (°) for 1b are presented in Tables 1-3 , respectively. Thus, 1b crystallizes in a P2 1 2 1 2 1 space group having four molecules to the unit cell. The molecular structure and the crystal structure of 1b are presented in Figs. 4 and 5, respectively. The bond distances and bond angles have the expected values for this kind of steroid. In particular, the enone O@C-C@C fragment in ring A is almost anti-periplanar with a small dihedral angle of 3.55°(see Table 3 ). The bond distances are 1.222(4) for O1-C3, 1.440(4) for C3-C4, and 1.336(4) Å for C4-C5, respectively.
The X-ray crystal structure of 1b reveals that it is aligned as a zigzag array connected by intermolecular hydrogen bonds between the oxygen atom at C-3 (O1) and the hydroxy-group (O2) of the neighboring molecule along the b axis with an O1ÁÁÁO2 distance of 2.743(3) Å. These arrays are arranged in a head-to-tail manner, and form a molecular layer parallel to the bc-plane. Also shown in Fig. 5 , the rigid steroid rings create a large free space into which the side chain is located. Furthermore, because of the absence of strong intermolecular interactions, the C 8 alkyl (cholestane) side chain is quite flexible and, therefore, the thermal motion in that part of the molecule is large. As a consequence, C-26, C-27 and the methine hydrogen atom at the terminal isopropyl group are disordered mutually over three positions due to the free rotation around the C-24-C-25 bond. As a result of the refinements, the site occupancy factor of C-27 was almost 1.0, and C-26 was divided in C-26-1 and C-26-2 with site occupancy factors of 0.60 and 0.40, respectively. The methine hydrogen atom of the isopropyl group was not included in the refinement process. Thus, X-ray analysis provided conclusive evidence for the stereochemical structure of 1b, resolving the A/B-ring juncture in the steroid nucleus and the terminal isopropyl group at the C 8 cholestane side-chain.
In conclusion, we report herein the chemical synthesis of 1a and 1b from 2a and 2b, respectively. The synthesis proceeded through easily prepared, well defined intermediates and provided analytically pure products. The availability of 1a and 1b will permit further studies on their plasma levels and facilitate studies on the mechanism by which 1b (and possibly 1a) enters plasma, presumably as a component of secreted lipoproteins. It will be of interest to determine whether plasma levels of 1a also correlate with the rate of bile acid synthesis, and if so, which intermediate (1a or . The molecular structure of 1b with numbered atoms. Thermal ellipsoids are drawn at 30% of probability. 1b) shows a better correlation. In addition, the compounds are now available as substrates for ensuing biosynthetic transformations catalyzed by 12a-hydroxylase (acting on 1b) as well as the D
4
-3-oxosteroid 5b-reductase (acting on both 1a and 1b) [16] .
Experimental
Materials
CA (2a) was obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). CDCA (2b) was supplied from Mitsubishi Tanabe Pharma Co. (Tokyo, Japan). All other chemicals and solvents were of analytical reagent grade and available from commercial sources. All compounds were dried by azeotropic distillation prior to use.
Instruments
All melting points (mp) were determined on a micro hot stage apparatus and are uncorrected. were also performed. High-resolution mass spectra by electrospray ionization (HR-ESI-MS) or by atmospheric pressure chemical ionization (HR-APCI-MS) were carried out using a JEOL AccuTOF JMS-T100LC liquid chromatography-mass spectrometer equipped with an ESI source or an APCI source and coupled to a Agilent 1200 series binary pump (Agilent Technologies Inc., Santa Clara, CA, USA) operated in the negative ion mode or positive ion mode.
High-performance liquid chromatography (HPLC) was obtained a Jasco LC-2000 plus HPLC system, consisting of two PU-2085 high-pressure pumps, a MX-2080-32 solvent mixing module, and a CO-2060 column heater equipped with a Chrom-NAV data processing system (Tokyo, Japan). The column was a Capcell Pack type AQ C18 (particle size, 3 lm, 250 mm Â 3.0 mm I.D.; Shiseido, Tokyo, Japan) kept at 37°C. The detector was an Alltech 2000ES evaporative light-scattering detector (Deerfield, IL, USA) operated under the following conditions: the flow rate of purified compressed air used as a nebulizing gas was 1.8 L/ min, and the temperature of the heated drift was 68.3°C (1a) or 65.5°C (1b). The mobile phase used was a mixture of 15 mM-ammonium acetate/acetic acid buffer solution (pH 5.4) and methanol [15:85 (1a) or 1:9 (1b), v/v]; the flow rate was kept at 0.4 lL/min during the analysis. Analytical thin-layer chromatography (TLC) was performed on pre-coated silica gel plates (E. Merck, Darmstad, Germany) using EtOAc-hexane mixtures as the developing solvent. IBX was prepared, according to the following procedure [14] . In short, to a solution of 2-iodobenzene (1.0 g, 4 mmol) in water (13 mL) was added OXONE Ò (monopersulfate compound; 2KHSO 5 / KHSO 4 /K 2 SO 4 ; 3.62 g, 5.8 mmol). The resulting suspension was stirred at 70°C for 3.5 h and then at 5°C for 1.5 h. The precipitated semi-crystalline solid was filtered, washed with water and acetone, and dried at room temperature for 16 h to afford IBX, which was directly used without further purification. ''Caution! IBX is explosive at high temperature.''
3a,7a,12a-Triacetoxy-5b-cholan-24-ol (4a)
A mixture of CA peracetate 3a (11.8 g, 22.1 mmol), Et 3 N (4 mL, 28.7 mmol) in dry THF (100 mL), and ethyl chloroformate (2.8 mL, 29.4 mmol) was stirred at room temperature for 2 h. To the resulting milky turbid suspension, NaBH 4 (4.0 g, 106 mmol) and then methanol (10 mL) were added gradually with ice-bath cooling, until a clear solution was obtained. After further stirring at 0°C for 2 h, the reaction product was extracted with EtOAc. The combined extract was washed with saturated brine, dried over Drierite, and evaporated to dryness. The oily residue was chromatographed on a silica gel column (250 g). Elution with hexane-EtOAc (7:3, v/v) afforded the corresponding 24-hydroxy-3,7,12-triacetate 4a which was recrystallized from Et 2 O-hexane as colorless thin plates; yield, 6.9 g (60%); mp, 134-135°C. 1 
3a,7a-Diacetoxy-5b-cholan-24-ol (4b)
The C-24 carboxyl group of CDCA diacetate 3b (12.0 g, 25 mmol) [obtained from CDCA (2b)], was reduced by the procedure described for the preparation of 4a to give 24-hydroxy-3, 7-diacetate 4b, which was recrystallized from Et 2 O-hexane as colorless thin plates; yield, 6.9 g (59%); mp, 160-162°C (literature value: mp, 159°C) [17] . 1 
3a,7a,12a-Triacetoxy-5b-cholan-24-al (5a)
To a solution of the 24-hydroxy-3,7,12-triacetate 4a (1.0 g, 1.9 mmol) in CH 2 Cl 2 (50 mL), 2,2,6,6-tetramethylpiperidine1-oxyl free radical (TEMPO) (7 mg, 45 lmol), and KBr (24 mg) were added gradually with ice-bath cooling. To the mixture, a solution of NaOCl (2 mL) dissolved in a buffer solution (pH 8.6, 14 mL) prepared from 0.5 M sodium bicarbonate, and 0.05 M sodium carbonate was added. The mixture was stirred at 0°C for 20 min; the reaction was monitored by TLC using hexane-EtOAc (1:1, v/v) as the developing solvent. After adding methanol (1 mL), the reaction product was extracted with CH 2 Cl 2 . The combined extract was washed with water, dried over Drierite, and evaporated to dryness to give the crude 24-aldehyde-3,7,12-triacetate 5a. Recrystallization from methanol afforded the analytically pure 5a as colorless thin plates; yield, 790 mg (80%); mp, 86-87°C (literature value: mp, 55°C) [18] . 
3a,7a-Diacetoxy-5b-cholan-24-al (5b)
The 24-hydroxy-3,7-diacetate 4b (1.0 g, 2.16 mmol) was converted to the corresponding 24-aldehyde-3,7-diacetate 5b by the TEMPO oxidation as described for the preparation of 5a. 3.3.6. 3a,7a,12a-Triacetoxy-5b-cholest-24-ene (6a)
To a magnetically stirred solution of isopropyltriphenylphosphonium iodide (230 mg, 0.53 mmol) in dry THF (5 mL), a solution of 1.6 M n-BuLi in hexane (330 lL) was added slowly with ice-bath cooling. The mixture was stirred at 0°C for 30 min. To this mixture, a solution of the 24-aldehyde-3,7,12-triacetate 5a (100 mg, 0.19 mmol) and tri[2-(2-methoxyethoxy)ethyl]amine (10 lL) dissolved in dry THF (5 mL) was then added, and the mixture was further stirred at 0°C for 15 min. After quenching the reaction by the addition of acetone (2 mL), the reaction product was extracted with CH 2 Cl 2 . The combined extract was washed with water, dried over Drierite, and evaporated to give a light yellow residue. Acetylation of the residue by the usual method and subsequent work-up by solvent extraction gave the crude reaction product. Chromatography of the product on a column of silica gel (5 g 
3a,7a-Diacetoxy-5b-cholest-24-ene (6b)
The 24-aldehyde-3,7-diacete 5b (900 mg 1.95 mmol), was subjected to the Wittig reaction with isopropyltriphenylphosphonium iodide and processed as described for the preparation of 6a. The procedure afforded the D 24 -3,7-diacetate 6b which crystallized from methanol as colorless needles; yield, 552 mg (58%); mp, 74-76°C (literature value: mp, 67-69°C) [19] . 93 (s, 3H, 19-H 3 ), 1.60 (s, 3H, 27-H 3 ), 1.68 (s, 3H, 26-H 3 ), 2.03, 2.05 (each s, 3H, OCOCH 3 ), 4.59 (m, 1H, 3b-H), 4.88  (brs, 1H, 7b-H), 5.09 (m, 1H, 24-H) . 13 The D 24 -3,7,12-triacetate 6a (60 mg, 0.11 mmol) in a mixed solvent (20 mL) of EtOAc-methanol-acetic acid (10:10:1, v/v/v) was hydrogenated in the presence of 10% Pd/C catalyst (6 mg) under a slight positive pressure. After stirring at room temperature for 3 h, the catalyst was removed by filtration through Celite, and the solvent of the mother liquor was evaporated under reduced pressure to give a pale yellow oil of 5b-cholestane 3,7,12-triacetate (7a). Although 7a was found to be homogeneous according to TLC, HPLC, and NMR analyses, it resisted crystallization attempts; yield, 58.8 mg (98%). 3.3.9. 3a,7a-Diacetoxy-5b-cholestane (7b) Catalytic hydrogenation of D 24 -3,7-diacetate 6b (100 mg, 0.21 mmol) by the procedure as described for the preparation of 7a gave the 5b-cholestane 3,7-diacetate (7b); yield, 98 mg (98%); mp, 85-87°C (recrystallized from methanol as colorless thin plates) (literature value: mp, 83-87°C) [20] . 
7a,12a-Diacetoxy-5b-cholestan-3a-ol (8a)
A mixture of the 5b-cholestane 3,7,12-triacetate 7a (500 mg, 0.91 mmol) and conc. HCl (6 drops) in methanol (15 mL) was slow stirred at 30°C for 6 h. Most of the solvent was evaporated under reduced pressure, and the reaction product was extracted with EtOAc. The combined extract was washed with saturated brine, dried over Drierite, and evaporated to dryness. The oily residue was chromatographed on a column of silica gel (15 g 3.3.11. 7a-Acetoxy-5b-cholestan-3a-ol (8b) 3-Hydroxy-7-acetate 8b was prepared from the 5b-cholestane 3,7-diacetate 7b (600 mg, 1.23 mmol) by selective hydrolysis at C-3 using concentrated HCl as described for the preparation of 8a. Crystallization of the crude product from EtOAc gave colorless needles; yield, 437 mg (80%); mp, 145-146°C. 3.3.12. 7a,12a-Diacetoxy-5b-cholestan-3-one (9a) Jones reagent (0.6 mL) was added gradually to a stirred solution of the 3-hydroxy-7,12-diacetate 8a (300 mg, 0.59 mmol) in acetone (8 mL) and CH 2 Cl 2 (1.5 mL) until the solution became dark brown. After stirring at 0°C for 30 min, 2-propanol (0.8 mL) was added to the mixture. The reaction product was extracted with CH 2 Cl 2 . The combined extract was washed with water, dried over Drierite, and evaporated to afford the 3-oxo-7,12-diacetate 9a which crystallized from EtOAc as colorless needles; yield, 248 mg (83%); mp, 171-172°C. 
7a-Acetoxy-5b-cholestan-3-one (9b)
The 3-hydroxy-7-acetate 8b (400 mg, 0.90 mmol), subjected to the oxidation reaction with Jones reagent and processed as described for the preparation of 9a, afforded a homogeneous oily product of the 3-oxo-7-acetate 9b, which resisted crystallization attempts; yield, 372 mg (93%). 3.3.14. 7a,12a-Dihydroxy-5b-cholestan-3-one (10a) The 3-oxo-7,12-diacetate 9a (200 mg, 0.40 mmol) was completely hydrolyzed in 10% methanolic KOH (3.5 g) at 30°C for 16 h. Most of the solvent was evaporated off, and the residue was dissolved in water and acidified with 10% HCl with stirring and ice-bath cooling. The precipitate was collected by filtration and washed with water. Recrystallization from methanol gave the 7,12-dihydroxy-3-one 10a as colorless thin plates; yield, 149 mg (90%); mp, 195-197°C (literature value: mp, 209-210°C) [21] . 
7a-Hydroxy-5b-cholestan-3-one (10b)
The 3-oxo-7-acetate 9b (300 mg, 0.67 mmol), subjected to complete hydrolysis with 10% methanolic KOH (6 g) at 30°C for 16 h and processed as described above, afforded the 7-hydroxy-3-one 10b; yield, 266 mg (98%); mp, 62-65°C (colorless needles from petroleum ether) (literature value: mp, 122-123°C) [22] . A solution of the 7,12-dihydroxy-3-one 10a (200 mg, 0.48 mmol) in 98% formic acid (2 mL) containing one drop of 60% perchloric acid was stirred at room temperature for 1 h. Acetic anhydride (2 mL) was added slowly with ice-bath cooling, and then the mixture was poured into ice. The precipitated solid was filtered, washed with water, and the product (11a) was recrystallized from methanol 11a as colorless thin plates; yield, 218 mg (96%); mp, 176-178°C. The 7-hydroxy-3-one 10b (250 mg, 0.62 mmol) was converted to the 3-oxo-7-formate 11b by the method described for the preparation of 11a. Although this compound was analytically pure by TLC, and NMR, it resisted crystallization attempts; yield, 182 mg (68%). To a magnetically stirred solution of the 3-oxo-7,12-diformate 11a (50 mg, 0.11 mmol) in DMSO (5 mL) was added freshly prepared IBX (40 mg, 0.28 mmol) and two drops of trifluoroacetic acid; the mixture was stirred at 40°C for 40 h. After cooling to room temperature, the reaction product was extracted with EtOAc, and the combined extract was washed with saturated brine, dried over Drierite, and evaporated to dryness. The crude product was purified on a silica gel column (3 g 
7a-Formyloxy-4-cholesten-3-one (12b)
The 3-oxo-7-formate 11b (200 mg, 0.46 mmol), subjected to the dehydration with IBX and processed as described for the preparation of 12a, afforded an oily residue. Chromatography of the oily product on a silica gel column (10 g) and elution with EtOAc-hexane (1:9, v/v) gave the conjugated 3-oxo-D 4 -7-formate 12b which recrystallized from acetone as colorless thin plates; yield, 127 mg (64%); mp, 152-155°C. as colorless needles; yield, 11 mg (80%); mp, 147-148°C. 1 H-NMR
